Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(60%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
3
60%
Ph phase_3
1
20%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Completed(1)

Detailed Status

Recruiting3
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (60.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)

Trials by Status

completed120%
not_yet_recruiting120%
recruiting360%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_3

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT07452198
recruitingphase_1

A Study of GR1803 in Systemic Lupus Erythematosus

NCT07348055
completedphase_1

Phase I Trial of GR1803 Injection in Patients With RRMM

NCT07102706
not_yet_recruitingphase_1

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

NCT07090954
recruitingphase_2

GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

NCT06566547

Clinical Trials (5)

Showing 5 of 5 trials
NCT07452198Phase 3

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
NCT07348055Phase 1

A Study of GR1803 in Systemic Lupus Erythematosus

Recruiting
NCT07102706Phase 1

Phase I Trial of GR1803 Injection in Patients With RRMM

Completed
NCT07090954Phase 1

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

Not Yet Recruiting
NCT06566547Phase 2

GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5